Welcome to our dedicated page for ARCH THERAPEUTICS news (Ticker: ARTH), a resource for investors and traders seeking the latest updates and insights on ARCH THERAPEUTICS stock.
Arch Therapeutics, Inc., a biotechnology company based in the United States, focuses on developing and marketing products utilizing its AC5 self-assembling technology platform. The company's products aim to stop bleeding, control leaking, and manage wounds during surgery, trauma, or from disease. Arch Therapeutics offers flagship products like the AC5 Advanced Wound System and AC5 Topical Hemostat for skin applications. Founded in 2006, the company is headquartered in Framingham, Massachusetts.
Arch Therapeutics (OTCQB: ARTH) announced the completion of a private placement, raising approximately $3.5 million through senior secured convertible notes. These notes earn 10% interest and are convertible into 107,872,668 shares at a conversion price of $0.0457. The financing will support Arch's goal of uplisting to a national exchange by early 2023 and advancing its commercialization strategy. Arch's products aim to improve wound care outcomes, especially for challenging cases. They also issued warrants for 85,110,664 shares at an exercise price of $0.0497.
Arch Therapeutics (OTCQB: ARTH) announced updates on its reimbursement strategy for the AC5 Advanced Wound System. The company is deploying the initial A4100 code and plans to submit a specific HCPCS product code application in the second quarter. The wind-down of the successful Pilot Program will transition into a multi-site clinical study aimed at enhancing payor adoption. The study is scheduled for the third quarter of 2022, targeting wound closure outcomes. These efforts are projected to boost sales in non-government facilities and clinics.
Arch Therapeutics, Inc. (OTCQB: ARTH) hosted a live interview featuring notable wound care experts, Dr. Terry Treadwell and Dr. Brock Liden, during the 2022 Symposium on Advanced Wound Care. They discussed the innovative AC5® Advanced Wound System, highlighting its effectiveness in treating chronic and acute wounds, including diabetic foot ulcers. The event showcased case studies that revealed significant healing benefits and potential healthcare savings. Arch continues to advance wound care technology, receiving regulatory approvals for its products in the U.S. and Europe.
Arch Therapeutics (OTCQB: ARTH) announced positive outcomes from clinical case reports on its AC5® Advanced Wound System at the 2022 Symposium on Advanced Wound Care. Presentations highlighted its efficacy in treating challenging wounds, potentially averting amputations and optimizing wound beds for skin grafts. CEO Terrence Norchi remarked on its transformative potential in interventional wound care. The company has regulatory approval to market AC5 in the US and Europe, indicating strong commercialization prospects.
Arch Therapeutics (OTCQB: ARTH) has announced that its AC5® Advanced Wound System will be featured in two clinical case report abstracts at the 2022 Symposium on Advanced Wound Care (SAWC) from April 6-10 in Arizona. The FDA has authorized the marketing of AC5, while its counterpart has received a CE mark in Europe. A live session will present additional case studies, highlighting the product's potential in addressing chronic wounds. Over 1,000 specialists are expected to attend, showcasing the growing interest in Arch's innovative wound care solutions.
Arch Therapeutics (OTCQB: ARTH) announced a distribution agreement with Centurion Therapeutics to enhance sales of its AC5® Advanced Wound System in non-government hospitals. This partnership leverages Centurion's extensive network of wound care distributors, aiming to broaden Arch's market presence. The AC5® system, FDA-approved for various wound types, shows promising early results in clinical settings. Arch's executives emphasize this deal as a significant step in their commercialization strategy, focusing on improving patient outcomes in acute and chronic wound management.
Arch Therapeutics (OTCQB: ARTH) announced significant findings regarding its AC5® Advanced Wound System in a recently published study. The system showed improved healing in nonhealing wounds after just 3 to 6 applications, requiring only weekly clinic visits. The study highlighted that AC5® effectively interrupted the inflammatory phase and stimulated proper healing, particularly in patients with serious comorbidities. AC5® has received FDA marketing authorization and aims to reduce healthcare burdens while enhancing patients' quality of life.
Arch Therapeutics, Inc. (OTCQB: ARTH) announced the appointment of Guy Fish, M.D. to its Board of Directors on January 4, 2022. Dr. Fish brings extensive experience in the medical field, currently serving as CEO of the Greater Lawrence Family Health Centers. His background includes a bachelor’s degree from Harvard and both MD and MBA from Yale. CEO Terrence W. Norchi expressed optimism about Dr. Fish's potential to guide Arch’s strategic direction, especially following the resignation of Jim Sulat, a long-serving board member. Arch develops innovative wound care and biosurgical devices, with regulatory approval for AC5® Advanced Wound System.
Arch Therapeutics has significantly expanded access to its AC5® Advanced Wound System by securing a spot on the Federal Supply Schedule and General Services Administration contracts. Effective December 15, 2021, all federal agencies, including the Department of Veterans Affairs and Department of Defense, can procure the AC5® system. This milestone enhances accessibility for managing complex wounds and aims to improve patient outcomes and cost efficiencies across federal healthcare systems.
Arch Therapeutics, Inc. (OTCQB: ARTH) announced a new interview featuring Dr. Christopher Gauland as part of its Experts in Wound Care Program. In the interview, Dr. Gauland provides insights on treating diabetic foot ulcers (DFUs) and discusses the effectiveness of AC5® Advanced Wound System in improving patient outcomes. The discussion highlights the severity of DFUs, where 48% remain unhealed within a year and 17% lead to amputation. The interview is available online, contributing to Arch's mission of advancing wound care through expert insights.
FAQ
What is the current stock price of ARCH THERAPEUTICS (ARTH)?
What is the market cap of ARCH THERAPEUTICS (ARTH)?
What does Arch Therapeutics, Inc. do?
Where is Arch Therapeutics, Inc. headquartered?
When was Arch Therapeutics, Inc. founded?
What are the flagship products of Arch Therapeutics, Inc.?
What is the focus of products developed by Arch Therapeutics, Inc.?
What is the contact information for Arch Therapeutics, Inc. Investor Relations?
Who is the Chief Financial Officer of Arch Therapeutics, Inc.?
What are the investigational devices offered by Arch Therapeutics, Inc.?
What are the trademarks associated with Arch Therapeutics, Inc.?
What is a significant milestone planned by Arch Therapeutics, Inc.?
